HBsAg level defines different clinical phenotypes of HBeAg(-) chronic HBV infection related to HBV polymerase-specific CD8

HBV eAg(-) infection gray-zone HBV immune control HBV inactive carrier HBsAg functional HBV-specific CD8 + T-cell response liver fibrosis progression

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 11 12 2023
accepted: 29 02 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

HBe-antigen(Ag)-negative chronic hepatitis B virus (HBV) infection is characterized by little liver fibrosis progression and vigorous HBV-multispecific CD8 To assess whether HBsAg level could discriminate different HBeAg-negative chronic HBV infection subtypes with dissimilar quality of HBV-specific CD8 We recruited 63 HBeAg-negative chronic HBV infection patients in which indirect markers of liver inflammation/fibrosis, portal pressure, viral load (VL), and HBV-specific CD8 A positive linear trend between HBsAg level and APRI, liver stiffness (LS), liver transaminases, and HBV VL, and a negative correlation with platelet count were observed. Frequency of cases with HBV-specific CD8 HBsAg > 1,000 IU/ml HBeAg-negative chronic HBV infection group shows indirect data of higher degree of inflammation, liver stiffness, and fibrosis progression speed, which are related to an impaired HBV-polymerase-specific CD8

Sections du résumé

Background UNASSIGNED
HBe-antigen(Ag)-negative chronic hepatitis B virus (HBV) infection is characterized by little liver fibrosis progression and vigorous HBV-multispecific CD8
Aims UNASSIGNED
To assess whether HBsAg level could discriminate different HBeAg-negative chronic HBV infection subtypes with dissimilar quality of HBV-specific CD8
Methods UNASSIGNED
We recruited 63 HBeAg-negative chronic HBV infection patients in which indirect markers of liver inflammation/fibrosis, portal pressure, viral load (VL), and HBV-specific CD8
Results UNASSIGNED
A positive linear trend between HBsAg level and APRI, liver stiffness (LS), liver transaminases, and HBV VL, and a negative correlation with platelet count were observed. Frequency of cases with HBV-specific CD8
Conclusion UNASSIGNED
HBsAg > 1,000 IU/ml HBeAg-negative chronic HBV infection group shows indirect data of higher degree of inflammation, liver stiffness, and fibrosis progression speed, which are related to an impaired HBV-polymerase-specific CD8

Identifiants

pubmed: 38545116
doi: 10.3389/fimmu.2024.1352929
pmc: PMC10966405
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1352929

Informations de copyright

Copyright © 2024 Peña-Asensio, Calvo-Sánchez, Miquel-Plaza, Sanz-de-Villalobos, González-Praetorius, Delgado-Fernandez, Torralba and Larrubia.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Julia Peña-Asensio (J)

Department of Biology of Systems, University of Alcalá, Alcalá de Henares, Spain.
Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.

Henar Calvo-Sánchez (H)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.
Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.
Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Spain.

Joaquín Miquel-Plaza (J)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.
Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.

Eduardo Sanz-de-Villalobos (E)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.
Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.

Alejandro González-Praetorius (A)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.
Section of Microbiology, Guadalajara University Hospital, Guadalajara, Spain.

Alberto Delgado-Fernandez (A)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.

Miguel Torralba (M)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.
Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Spain.
Service of Internal Medicine, Guadalajara University Hospital, Guadalajara, Spain.

Juan-Ramón Larrubia (JR)

Translational Research Group in Cellular Immunology, Instituto de Investigación Sanitaria de Castilla La-Mancha (IDISCAM), Toledo, Spain.
Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.
Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Spain.

Classifications MeSH